|1.||Yamashita, Nobuyuki: 4 articles (07/2011 - 07/2006)|
|2.||Chayama, Kazuaki: 2 articles (04/2014 - 07/2011)|
|3.||Kuzuhara, Hiroyuki: 2 articles (07/2008 - 07/2006)|
|4.||Nishiyama, Shoji: 2 articles (07/2008 - 07/2006)|
|5.||Kurosawa, Tohru: 2 articles (11/2007 - 07/2006)|
|6.||Imawari, Michio: 1 article (04/2014)|
|7.||Okita, Kiwamu: 1 article (04/2014)|
|8.||Onishi, Saburo: 1 article (04/2014)|
|9.||Kaneko, Shuichi: 1 article (04/2014)|
|10.||Enomoto, Nobuyuki: 1 article (04/2014)|
08/01/2003 - "Therefore, we demonstrate that ME3738 triggers IL-6 expression, which activates pathways that are relevant to protect from Con A-induced liver failure."
08/01/2003 - "In addition, ME3738 did not protect IL-6(-/-) animals from Con A-induced liver failure, while IL-6 injection was still effective. "
08/01/2003 - "ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism."
01/01/2007 - "It has been demonstrated that ME3738 is stimulate to produce IL-6 and that it protects against concanavalin A-induced liver failure. "
07/17/2006 - "Protective effects of alpha1-acid glycoprotein and serum amyloid A on concanavalin A-induced liver failure via interleukin-6 induction by ME3738."
|2.||Chronic Hepatitis C
04/01/2014 - "The present clinical study of ME3738 was conducted in naïve chronic hepatitis C patients to investigate the sustained virological response (SVR) and safety of 48-week treatment with ME3738 plus PEG IFN-α-2a. "
04/01/2014 - "ME3738 plus PEG IFN-α-2a treatment to naïve chronic hepatitis C patients showed an antiviral effect and a good safety profile up to 48 weeks. "
04/01/2014 - "Subjects (n = 135) with genotype 1b chronic hepatitis C with high viral loads were divided into three groups (ME3738 50 mg b.i.d., 200 mg b.i.d. "
07/01/2011 - "ME3738 inhibited HCV replication, enhancing the effect of IFN-α to increase ISG expression both in vitro and in vivo, suggesting that the combination of ME3738 and IFN might be useful therapeutically for patients with chronic hepatitis C."
07/01/2008 - "Hepatic Hyp content and the area of hepatic fibrosis in BDL rats treated with ME3738 were reduced by 24% and 39% compared with non-treated BDL rats (hepatic Hyp, 9.40 +/- 2.85 vs. 12.39 +/- 3.91 mg/liver; P = 0.036; area of hepatic fibrosis, 13.1 +/- 3.8 vs. 21.5 +/- 10.9; P = 0.045). "
07/01/2008 - "The aim of this study was to examine the preventive effects of ME3738 on hepatic fibrosis induced by bile duct ligation (BDL) in rats. "
07/01/2008 - "Preventive effects of ME3738 on hepatic fibrosis induced by bile duct ligation in rats."
07/01/2008 - "Oral ME3738 administration may prevent the progression of hepatic fibrosis in BDL rats through suppression of the activation and collagen synthesis of HSC and, in part, oxidative stress. "
|5.||Liver Diseases (Liver Disease)
11/28/2007 - "ME3738 (22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol), a derivative of soyasapogenol, attenuates liver disease in several models of chronic liver inflammation. "
08/01/2003 - "ME3738 is a new compound that attenuates liver disease in several models of acute and chronic liver inflammation. "
07/01/2011 - "ME3738 (22β-methoxyolean-12-ene-3β, 24-diol), a derivative of soyasapogenol B, attenuates liver disease in several animal models of acute and chronic liver injury. "
|1.||Interleukin-6 (Interleukin 6)
|4.||Serum Amyloid A Protein (Serum Amyloid A)
|5.||Ethanol (Ethyl Alcohol)
|7.||Interferon-alpha (Interferon Alfa)
|8.||RNA (Ribonucleic Acid)